skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms

Original Research

(2167) Views  (609) Full article downloads

Authors: Joseph Tripodi, Ronald Hoffman, Vesna Najfeld, et al

Published Date September 2010 Volume 2010:2 Pages 219 - 223
DOI: http://dx.doi.org/10.2147/CMAR.S12829

Joseph Tripodi1, Ronald Hoffman1, Vesna Najfeld2, Rona Weinberg3
1The Myeloproliferative Disorders Program, Tisch Cancer Institute, Department of Medicine and 2Department of Medicine and Pathology, Mount Sinai School of Medicine, 3The Myeloproliferative Disorders Program, Cellular Therapy Laboratory, The New York Blood Center, New York, NY, USA

Abstract: The Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, are a group of clonal hematopoietic stem cell disorders with overlapping clinical and cytogenetic features and a variable tendency to evolve into acute leukemia. These diseases not only share overlapping chromosomal abnormalities but also a number of acquired somatic mutations. Recently, mutations in a putative tumor suppressor gene, ten-eleven translocation 2 (TET2) on chromosome 4q24 have been identified in 12% of patients with MPN. Additionally 4q24 chromosomal rearrangements in MPN, including TET2 deletions, have also been observed using conventional cytogenetics. The goal of this study was to investigate the frequency of genomic TET2 rearrangements in MPN using fluorescence in situ hybridization as a more sensitive method for screening and identifying genomic deletions. Among 146 MPN patients, we identified two patients (1.4%) who showed a common 4q24 deletion, including TET2. Our observations also indicated that the frequency of TET2 deletion is increased in patients with an abnormal karyotype (5%).

Keywords: TET2, myeloproliferative neoplasms, fluorescence in situ hybridization, cytogenetics






Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Role of lapatinib in the first-line treatment of patients with metastatic breast cancer
Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab
Cetuximab in the treatment of head and neck cancer: preliminary results outside clinical trials
Treatment of cutaneous melanoma: current approaches and future prospects
Positive response to neoadjuvant cyclophosphamide and doxorubicin in topoisomerase II nonamplified/HER2/neu negative/polysomy 17 absent breast cancer patients
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Local tumor progression following lipiodol-based targeted chemoembolization of hepatocellular carcinoma: a retrospective comparison of miriplatin and epirubicin
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University